# EDGAR Filing Document

**Accession Number:** 0000901832
**File Stem:** 0001654954-26-003979
**Filing Date:** 2026-4
**Character Count:** 12778
**Document Hash:** dd737c28b5b58be78e95e26fa3aa293d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-003979.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001654954-26-003979

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260428

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 26903150

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422

**FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of April 2026

Commission File Number: 001-11960

 **AstraZeneca PLC**

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

 **AstraZeneca PLC**

INDEX TO EXHIBITS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

 ***1.***

**Breztri approved in the US for asthma**

28 April 2026

 ***Breztri* approved in the US for asthma as first and only triple therapy for patients 12 years of age and older**

 ***Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca's single-inhaler fixed-dose triple therapy compared with inhaled dual therapy***

 ***Approval is second indication for Breztri beyond COPD***

AstraZeneca's fixed-dose triple-combination therapy *Breztri Aerosphere* (budesonide/glycopyrrolate/formoterol fumarate or BGF 320/36/9.6lg) has been approved in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age and older. *Breztri* is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines with a long-acting muscarinic antagonist (LAMA). *Breztri* (320/18/9.6lg) was approved in the US in 2020 to treat adults with chronic obstructive pulmonary disease (COPD) and was prescribed to more than 6.8 million patients globally in 2025.<sup>1,2</sup>

The approval by the US Food and Drug Administration (FDA) was based on efficacy and safety data from the Phase III KALOS and LOGOS trials investigating *Breztri* in a broad population consisting of patients with asthma, with or without a recent asthma exacerbation.<sup>3</sup> In these trials, *Breztri* demonstrated a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled ICS/LABA.<sup>3</sup> In a key secondary endpoint, *Breztri* also demonstrated a rapid onset of action with a significant improvement from baseline in lung function within five minutes after the first dose.<sup>3</sup> *Breztri* is a maintenance therapy and is not used to relieve sudden breathing problems and will not replace a rescue inhaler.

Njira Lugogo, MD, Clinical Professor, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, said: "Despite the availability of dual maintenance therapy, many patients are still at risk for exacerbations and experience daily breathing difficulties, reduced lung function and the ongoing fear of worsening symptoms. The FDA approval of *Breztri* as the only maintenance triple therapy for people with asthma 12 years of age and older marks a pivotal moment in helping those living with this debilitating disease breathe better, sooner."

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca, said: "As the fastest growing fixed-dose triple-combination therapy in COPD, *Breztri* is already improving outcomes for people suffering with COPD, and we are proud to extend its benefits to asthma patients. The FDA's approval of *Breztri* in asthma demonstrates how our innovative science continues to bring new solutions for patients with respiratory diseases."

There are 27 million people living with asthma in the US,<sup>4</sup> around half of whom continue to be uncontrolled on dual therapies, leading to inflammation and muscle tightening in the airway (bronchoconstriction) that cause wheezing, breathlessness, chest tightness, coughing exacerbations and even death.<sup>5-7</sup> Nearly 10 million asthma attacks still occur each year in the US.<sup>4</sup>

Results from <u>KALOS and LOGOS</u> were published in *<u>The Lancet Respiratory Medicine</u>* in February 2026.<sup>3</sup> There were no new safety or tolerability signals identified for *Breztri* in the trials.<sup>3</sup>

 *Breztri* is a single-inhaler fixed-dose triple-combination therapy approved for the treatment of COPD in adults in 90 countries worldwide including the US, EU, China and Japan. Regulatory filings for *Breztri* in asthma are currently under review in other major regions including the EU, Japan and China.

 **<u>Notes</u>**

 **Asthma**

Asthma is a prevalent, chronic respiratory disease affecting as many as 262 million people worldwide,<sup>8</sup> including 27 million in the US.<sup>4</sup> When uncontrolled, inflammation and muscle tightening in the airway (bronchoconstriction) may cause wheezing, breathlessness, chest tightness, coughing, and even death.<sup>5-7</sup> Many patients remain uncontrolled despite the availability of standard of care medicines and continue to experience significant limitations on lung function and reduced quality of life.<sup>6,7</sup>

 **KALOS and LOGOS Phase III trials**

KALOS and LOGOS were replicate confirmatory, randomised, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials to assess the efficacy and safety of *Breztri Aerosphere* compared with S*ymbicort* (budesonide/formoterol fumarate, a marketed therapeutic option), PT009 (budesonide/formoterol fumarate in an *Aerosphere* formulation) and the *Symbicort* and PT009 treatment groups combined.<sup>3,9,10</sup> KALOS and LOGOS included approximately 4,300 randomised patients.

The primary endpoints for the two individual trials were a change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24 and trough FEV1 over 12-24 weeks and over 24 weeks.<sup>3,9,10</sup> The primary endpoints and treatment comparisons in the KALOS and LOGOS trials differed according to regulatory submission approaches. In the data package submitted to the US FDA, the primary lung function endpoint was change from baseline in FEV1 AUC0-3 at week 24, and the key secondary endpoint was change from baseline in morning pre-dose trough FEV1 at week 24, compared to PT009.<sup>3</sup>

 ***Breztri/Trixeo Aerosphere***

Budesonide/glycopyrronium/formoterol fumarate or budesonide/glycopyrrolate/formoterol fumarate, is approved under the brand name *Breztri Aerosphere* in Japan, China and the US, and *Trixeo Aerosphere* in the EU, is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, a LABA, glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), with budesonide, an ICS, and delivered via the *Aerosphere* pMDI. *Breztri/Trixeo Aerosphere* is approved to treat adults with COPD in 90 countries worldwide including the US, EU, China, Japan, and was prescribed to more than 6.8 million patients globally in 2025.<sup>2</sup>

 **AstraZeneca in Respiratory & Immunology**

Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company.

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.

 **<u>AstraZeneca</u>**

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit <u>astrazeneca.com</u> and follow the Company on Social Media <u>@AstraZeneca</u>.

 **Contacts**

For details on how to contact the Investor Relations Team, please click <u>here</u>. For Media contacts, click <u>here</u>.

 **References**

1. AstraZeneca. Breztri Aerosphere approved in the US for the maintenance treatment of COPD. Press Release. 24 July 2020. Available at: <u>https://www.astrazeneca.com/media-centre/press-releases/2020/breztri-aerosphere-approved-in-the-us-for-copd.html</u>. [Last accessed: April 2026].

2. AstraZeneca. Data On File. REF-325003.

3. Papi A, Wise R, Jackson D et al. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials*. The Lancet Respiratory Medicine*. 2026;14:350-362.

4. U.S. Centers for Disease Control and Prevention (CDC). Most Recent Asthma Data. [Online]. Available at: <u>https://www.cdc.gov/asthma-data/about/most-recent-asthma-data.html</u> [Last accessed: April 2026].

5. Fernandes AG, et al. Risk factors for death in patients with severe asthma. *J Bras Pneumol*. 2014;40(4):364-372.

6. Davis J, et al. Burden of asthma among patients adherent to ICS/LABA: A real-world study. *J Asthma*. 2019 Mar;56(3):332-340.

7. Buhl R, et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting b2-agonist in UK primary care settings. *Respir Med*. 2020 Feb;162:105859.

8. Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: <u>http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf</u>. [Last accessed: April 2026].

9. Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) [Online]. Available at: <u>https://clinicaltrials.gov/study/NCT04609878?limit=25&term=KALOS&rank=1</u>. [Last accessed: April 2026].

10. Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) [Online]. Available at: <u>https://clinicaltrials.gov/study/NCT04609904?limit=25&term=LOGOS&rank=4</u>. [Last accessed: April 2026].

 **Matthew Bowden**

 **Company Secretary**

 **AstraZeneca PLC**

 <u>SIGNATURES</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: **28 April 2026**

---

| |
|:---|
| By: /s/ Matthew Bowden |
| Name: Matthew Bowden |
| Title: Company Secretary |

---

<br>